Figure 3.
AdExTek inhibits the growth of well established 4T1 (A) and B16F10.9 (B) primary tumors. A murine mammary tumor (4T1) and a murine melanoma (B16F10.9) were implanted into the right flank of BALB/c and C57/BL6 mice, respectively (5 × 105 cells/mouse). After a palpable tumor was achieved (day 0), the mice were randomly divided into two groups for each tumor type. One group of mice received i.v. AdPacβ-gal, and the other group mice received AdExTek. Tumor size then was measured every 2 days for 12 days. Data were plotted as the mean ± SE. For some points error bars are smaller than symbols.